Bristol-Myers Squibb Company / IFM Therapeutics, LLC

Solid Tumors (Innate Immunity Immuno-Oncology)

2.0M US cases/yr

Disease Overview

Innate immunity agonists such as STING (Stimulator of Interferon Genes) and NLRP3 inflammasome activators aim to prime the immune system against tumors that fail to respond to checkpoint inhibitors. The opportunity targets the large 'cold tumor' population across solid tumors where PD-1/PD-L1 antibodies have limited activity, but the modality has historically struggled to translate strong preclinical signals into clinical benefit.

Competitive Landscape

When BMS bought IFM in August 2017, the STING agonist field was crowded but unproven: Aduro Biotech (with Novartis) had ADU-S100 in Phase 1, Merck was running ulevostinag (MK-1454), and GSK was developing GSK3745417, alongside efforts from Spring Bank, Eisai/Boston Pharma, and Takeda. NLRP3 agonism was earlier-stage and largely IFM-led. The deal gave BMS — already the I-O leader via Opdivo and Yervoy — first-in-class assets to combine with checkpoint inhibitors against PD-1-refractory tumors. The class subsequently disappointed: Merck discontinued ulevostinag after a 0% monotherapy ORR at 2018 ESMO, GSK halted GSK3745417 in solid tumors and AML, and Aduro/Novartis terminated ADU-S100. By 2025 no STING agonist had advanced to Phase 3, validating BMS's biobucks-heavy structure (only $300M upfront of $2.32B) but leaving the milestone payments largely unrealized. The deal's strategic value increasingly hinges on NLRP3 follow-on programs and the option value of combining innate immune activation with next-generation checkpoint and TCR therapies.